| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | Biologics | Nervous System | ||
Phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | Biologics | Nervous System | ||
Phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | Biologics | Nervous System |
Recent Updates
Recently added Catalysts
Voyager Therapeutics, Inc.$3.44
-0.23 (-6.25%)
D 33Pipeline Score Overvalued Biotech · Commercial
Market Cap
229.60 M
EPS
-1.98
P/E Ratio
-
Value Trade
1.62 M
SEC Financials
Q1 2026Dilution Risk
40%Revenue
2.59 M
R&D Expenses
24.60 M
Operating CF
-33.42 M
Total Assets
219.32 M
Total Liabilities
45.66 M
Equity
173.67 M
D/E Ratio
12,345
-10.38 %
Week
-5.24 %
1 Month
12.09 %
3 Month
-6.86 %
6 Month
-5.86 %
5 Year
-74.83 %
All Time
Cash Data
Cash Position
141.48 M
Monthly Burn
11.14 M
Runway
10.8 mo
Burn Trend
StableSEC Filing
May 7, 2026
Overview
Volume
716.46 K
52 Week Range
2.65 - 5.55
% held by Insiders
16.59 %
% held by Institutions
55.71 %
Enterprise Value
122.69 M
Total Shares
60.38 M
Short %
7.85 %
Float Shares
45.53 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Voyager Therapeutics, Inc.
565Total events
4Upcoming
80Tier-1 (high impact)
2015 – 2027Coverage
Upcoming catalysts 4
Event history 561
Q3 2026
Q3 2026
◆Topline ReadoutTAU01Clinical Data
Initial tau PET imaging data from MAD trial expected in second half of 2026
Alzheimer's diseasesource ↗
Jun 15, 2026
◆Oral PresentationPresentation
Voyager CEO to participate in pre-recorded fireside chat at H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference
May 13, 2026
▲Oral PresentationVY1706Presentation
Late-breaking oral presentation of 3-month GLP toxicology data for VY1706 at ASGCT 2026
Alzheimer's diseasesource ↗
May 12, 2026
◆Poster PresentationPresentation
Poster presentation on ApoE4/ApoE2 gene therapy in ApoE4 humanized mice
Alzheimer's diseasesource ↗
Q2 2026
Q2 2026
Q2 2026
◆Topline ReadoutVY7523Clinical Data
Initial tau PET imaging data from multiple ascending dose trial
Alzheimer's diseasesource ↗
Q2 2026
◆Trial InitiationTrial
Two I.V.-delivered neuro gene therapies to enter clinic H2 2026
neurological diseasessource ↗
Q2 2026
◆Timing GuidanceVY7523Presentation
VY7523 data in AD patients expected H2 2026
Alzheimer's Diseasesource ↗
Drug Pipeline Intelligence
D33
Pipeline Score $75M
Pipeline ValueOvervalued
Valuation Signal2
Drugs Scored0.3x
rNPV / MCap Top 41%
Micro Cap (rank 538 of 911)
Percentile RankVoyager Therapeutics, Inc. faces pipeline headwinds (33/100), with $587M risk-adjusted pipeline value, led by VP4896 in Alzheimer's Disease (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VP4896 Small molecule | Alzheimer's Disease | Phase 3 | NCT00231946 | 44% | $525M | COMPLETED | 555 | - | - | — | - | Sep 20, 2007 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
VY1706 | Alzheimer's disease | — | 2026-05-13 | well tolerated; no adverse clinical pathology or histopathological findings up to the highest dose tested (5E13 vg/kg); reduced tau protein up to 64% in key brain regions of non-human primates (NHPs) at 13 weeks following a single IV dose; dose-dependent reductions of up to 51-75% MAPT mRNA; 48-64% tau protein in key brain regions at 13 weeks in NHPs Read More | Voyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer’s Disease Expected H2 2026 Read More | |
VY1706 | Alzheimer's disease | — | 2026-05-13 | well tolerated; no adverse clinical pathology or histopathological findings up to the highest dose tested (5E13 vg/kg); reduced tau protein up to 64% in key brain regions of non-human primates (NHPs) at 13 weeks following a single IV dose; dose-dependent reductions of up to 51-75% MAPT mRNA; 48-64% tau protein in key brain regions at 13 weeks in NHPs Read More | Voyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer’s Disease Expected H2 2026 Read More | |
VY1706 | Alzheimer's disease | — | 2026-05-13 | well tolerated; no adverse clinical pathology or histopathological findings up to the highest dose tested (5E13 vg/kg); reduced tau protein up to 64% in key brain regions of non-human primates (NHPs) at 13 weeks following a single IV dose; dose-dependent reductions of up to 51-75% MAPT mRNA; 48-64% tau protein in key brain regions at 13 weeks in NHPs Read More | Voyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer’s Disease Expected H2 2026 Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in VYGR
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
VYGR Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-10-16 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-10-16 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-10-16 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
VYGRVoyager’s Tau-Targeted Gene Therapy VY1706 for Alzheimer’s Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026
Voyager Therapeutics announced that its investigational gene therapy VY1706 for Alzheimer's disease will be featured in a poster presentation at the Alzheimer's Association International Conference (AAIC) 2026. The therapy, which targets tau proteins, has received FDA clearance for clinical trials, with dosing expected to start in the second half of 2026. Preclinical studies show promising results in reducing tau levels and a favorable safety profile.
Read more →VYGRVoyager to Present at H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference
Voyager Therapeutics, Inc. will present at the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference. CEO Alfred W. Sandrock, Jr. will participate in a pre-recorded fireside chat, which will be available on-demand starting June 15, 2026. The company focuses on leveraging genetics to treat neurological diseases and has a diverse pipeline targeting various conditions.
Read more →VYGRVoyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer’s Disease
Voyager Therapeutics announced that the FDA has approved its IND application for VY1706, a gene therapy aimed at reducing tau protein levels associated with Alzheimer's disease. The company plans to initiate a clinical trial in the second half of 2026, focusing on adults with early-stage Alzheimer's. Preclinical studies have shown substantial reductions in tau levels and a favorable safety profile, indicating potential promise for this innovative treatment approach.
Read more →VYGRVoyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer’s Disease Expected H2 2026
Voyager Therapeutics presented promising data on VY1706, a gene therapy for Alzheimer's disease, at the ASGCT 2026 Annual Meeting. The three-month GLP toxicology study showed that VY1706 was well tolerated in non-human primates and significantly reduced tau protein levels. The company is on track to submit an IND application in Q2 2026, with clinical trials expected to start in H2 2026.
Read more →VYGRVoyager Reports First Quarter 2026 Financial and Operating Results
Voyager Therapeutics reported its first quarter 2026 financial results, highlighting a strong cash position of $172 million that supports operations into 2028. The company is preparing for clinical entry of its tau silencing gene therapy, VY1706, expected in the second half of 2026. Additionally, they anticipate significant data on tau knockdown as a treatment approach for Alzheimer's disease.
Read more →VYGRVoyager IV-Delivered CNS Gene Therapies Featured in Multiple Presentations at ASGCT 2026, Including Late Breaker on Tau-Targeted VY1706 for Alzheimer’s Disease
Voyager Therapeutics announced multiple presentations at the ASGCT 2026 Annual Meeting, highlighting their investigational gene therapy VY1706 for Alzheimer's disease. A late-breaking presentation will showcase three-month GLP toxicology data demonstrating the therapy's pharmacology and safety. The company plans to submit an IND application in Q2 2026, aiming for first-in-human dosing later in the year.
Read more →VYGR▼ -8.5%on this news· ran to -23% by day 3
Voyager Acquisition Corporation Announces Approval of Its Business Combination with Veraxa Biotech AG
Voyager Acquisition Corporation has obtained approval for its business combination with Veraxa Biotech AG, allowing the merger to proceed. Following the closing, the new entity is set to be listed on Nasdaq under the ticker 'VRXA'. Notably, approximately 99.67% of Voyager's Class A ordinary shares will be redeemed, leaving around $885,556 in the trust account. Veraxa specializes in developing next-generation antibody therapeutics, signifying a promising future for the combined firm.
Read more →VYGRVoyager Acquisition Corporation Announces Redemption Results in Connection with its Business Combination with VERAXA Biotech AG
Voyager Acquisition Corporation has announced that 25,217,315 of its Class A ordinary shares were redeemed, amounting to approximately 99.67% of the total outstanding shares in relation to its business combination with VERAXA Biotech AG. Following the expected redemptions, around $885,556 will remain in the trust account, and 82,685 Class A shares will convert into shares of VERAXA Biotech Holding AG. The merger is anticipated to establish the combined entity as a publicly traded company on NASDAQ under the symbol 'VRXA.' VERAXA aims to advance a pipeline of innovative antibody-based therapeutics.
Read more →VYGR▲ +5.4%on this news· ran to +28% by day 1shared move
Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results - Transformative year for tau in AD: VY1706 clinical entry and VY7523 clinical data anticipated H2 2026 - - Validating brain-targeted caps
Voyager Therapeutics has announced its fourth quarter and full year 2025 financial results, highlighting a transformative year for the company. Key developments include the anticipated clinical entry of VY1706 and expected clinical data for VY7523 in the second half of 2026. The company ended 2025 with a robust cash position that is projected to sustain operations through 2028. Furthermore, the advancement of the Voyager NeuroShuttle platform aims to enhance therapeutic delivery for neurological diseases.
Read more →VYGRVoyager to Present at Upcoming Investor Conferences
Voyager Therapeutics, Inc. announced its participation in upcoming investor conferences, including a webcast of an Oppenheimer fireside chat. The company focuses on leveraging genetics to treat neurological diseases and has a diverse pipeline targeting conditions like Alzheimer's and Parkinson's disease. The webcast will be accessible on their website, with a replay available for 30 days.
Read more →VYGRLeveraging Genetics to Treat Neurological Diseases Corporate Deck / January 2026 2 | Forward - Looking Statements This presentation contains forward - looking statements for the purposes of the safe harbor provisions und
Voyager Therapeutics has outlined its strategic focus on leveraging genetics to treat neurological diseases, particularly Alzheimer's, in its January 2026 corporate presentation. The company emphasizes the achievement of key preclinical and clinical milestones as part of its development pipeline, including the introduction of therapies targeting tau protein. Although there are optimistic financial forecasts regarding milestone payments, Voyager acknowledges various inherent risks, including regulatory uncertainties and external competition. The firm is managing a solid cash position expected to last until 2028 to support its ongoing projects.
Read more →VYGRTransition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal Dementia
Transition Bio and Voyager Therapeutics have announced a collaboration to develop small molecules targeting TDP-43 for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Transition Bio will lead the discovery and optimization of these molecules, with Voyager having the option to license the program. The partnership includes an upfront payment and potential milestone payments totaling up to $500 million.
Read more →VYGRVoyager Reports Third Quarter 2025 Financial and Operating Results
Voyager Therapeutics reported its third quarter 2025 financial results, highlighting a robust cash position of $229 million, which supports operations through 2028. The company is advancing its multi-modality pipeline, including the introduction of the Voyager NeuroShuttle program and a collaboration with Transition Bio to develop small molecules for ALS and FTD. Upcoming milestones include anticipated clinical data for its tau-targeting programs.
Read more →VYGR▲ +6.5%on this news· ran to +26% by day 3
Leveraging Genetics to Treat Neurological Diseases Citi 2025 Biopharma Back to School Conference
At the Citi 2025 Biopharma Back to School Conference, Voyager Therapeutics, Inc. (NASDAQ: VYGR) presented its strategic vision for leveraging genetics in treating neurological diseases. The company highlighted expectations for multiple clinical programs by 2026, with a focus on Alzheimer's treatments. Voyager aims to expand its gene therapy and antibody strategies while utilizing its TRACER capsid discovery platform for effective therapeutic delivery. Despite the optimism, forward-looking statements were accompanied by acknowledgment of various risks and uncertainties that could impact progress.
Read more →VYGRVoyager Reports Second Quarter 2025 Financial and Operating Results - Cash runway extended into 2028; expected to enable multiple meaningful clinical data read-outs - - APOE program added to pipeline; fourth asset in ind
Voyager Therapeutics has reported its second-quarter 2025 financial results, showcasing an extended cash runway projected to last until 2028. This extension positions the company to facilitate multiple upcoming clinical data read-outs and supports the integration of its fourth pipeline asset targeting Alzheimer's disease. Switching to financial specifics, while the firm incurred a net loss of $33,382, concerns remain due to increased operating losses compared to the previous year. However, the company is optimistic about future milestones, especially with a potential $2.6 billion in development-stage milestone payments.
Read more →VYGR▲ +6.3%on this news
Voyager Adds Fourth Wholly-Owned Alzheimer’s Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach
Voyager Therapeutics has launched a new program targeting apolipoprotein E (APOE) to treat Alzheimer's disease. This program utilizes a proprietary TRACER capsid to deliver a bifunctional payload that aims to decrease the expression of the high-risk APOE4 variant while increasing the protective APOE2 variant. The company plans to present early data from this program at a scientific meeting in 2025, further expanding its Alzheimer's pipeline.
Read more →VYGRVoyager to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
Voyager Therapeutics announced that CEO Alfred W. Sandrock, Jr. will participate in a pre-recorded fireside chat at the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference. The chat will be available on-demand starting June 17, 2025, and will be archived for at least 30 days. Voyager focuses on using genetics to treat neurological diseases.
Read more →VYGRVoyager Demonstrates ALPL Receptor-Mediated Blood-Brain Barrier Transport of Novel AAV Capsids in Molecular Therapy Publication
Voyager Therapeutics announced a peer-reviewed publication demonstrating the ability of alkaline phosphatase (ALPL) to facilitate the transport of a novel AAV capsid, VCAP-102, across the blood-brain barrier. This research indicates significant potential for enhanced gene therapy applications in neurological diseases, with promising results from preclinical studies showing high transduction rates in various brain regions. The findings support Voyager's ongoing development of gene therapy programs, with IND filings anticipated this year.
Read more →VYGR▼ -6.9%on this news
Voyager Reports First Quarter 2025 Financial and Operating Results - Tau silencing gene therapy VY1706 to be featured in oral presentation at ASGCT 2025; has shown up to 73% knockdown of tau mRNA in the CNS in NHPs follo
Voyager Therapeutics reported its first-quarter financial results for 2025, highlighting its tau silencing gene therapy VY1706, which is set to be presented at ASGCT 2025. The therapy has achieved up to a 73% knockdown of tau mRNA in the central nervous system in non-human primates. Voyager maintains a cash position of $295 million, projected to support operations until mid-2027, though it reported a net loss of $31 million for the quarter. The company continues to advance its pipeline, focusing on neurological diseases like Alzheimer's.
Read more →VYGRVoyager Next-Generation CNS Capsids Featured at ASGCT 28th Annual Meeting
Voyager Therapeutics announced multiple presentations at the ASGCT 28th Annual Meeting, showcasing advancements in gene therapies for Alzheimer's disease, including VY1706, which achieved a 73% knockdown of tau mRNA. The company highlighted the effectiveness of its TRACER capsids in transducing CNS cells and discussed enhancements to reduce immunogenicity. Two INDs are expected this year, signaling potential clinical advancements.
Read more →VYGR▼ -7.4%on this news
Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025
Voyager Therapeutics presented promising preclinical data on its tau-targeting therapies, VY1706 and VY7523, at the AD/PD™ 2025 conference. VY1706 demonstrated significant tau reduction in non-human primates, while VY7523 showed selectivity in targeting pathological tau. The company plans to file for IND in 2026 and will host a webcast to discuss these findings.
Read more →VYGRVoyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results - Tau silencing gene therapy VY1706 robustly reduced tau mRNA levels, with broad distribution, and was well-tolerated in NHP study; IND fi
Voyager Therapeutics has reported its financial results for Q4 and full year 2024, highlighting advancements in its tau-targeting therapies, VY1706 and VY7523. VY1706 demonstrated a robust reduction in tau mRNA levels and was well-tolerated in non-human primate studies. Meanwhile, VY7523 was well tolerated in healthy volunteers and is in trials for Alzheimer's patients, with initial tau PET imaging data expected in H2 2026. Despite significant financial losses, the company secured approximately $80 million in funding and projects a cash runway through mid-2027.
Read more →VYGRVoyager Therapeutics Announces Fourth Quarter 2024 Conference Call and Webcast
Voyager Therapeutics, Inc. announced that it will report its fourth quarter 2024 financial and operating results on March 11, 2025. Following the report, the company will host a conference call and webcast to discuss the results at 4:30 p.m. ET. The event will be accessible on Voyager's website, with a replay available for at least 30 days after the conclusion. Voyager focuses on developing treatments for major neurological diseases using its TRACER™ AAV capsid discovery platform.
Read more →VYGRVoyager Reports Positive Topline Data for Single Ascending Dose (SAD) Trial of Anti-Tau Antibody VY7523 and Initiates Multiple Ascending Dose (MAD) Trial in Alzheimer’s Disease
Voyager Therapeutics announced positive topline data from the single ascending dose (SAD) trial of its investigational anti-tau antibody VY7523, showing it is safe and well tolerated. The company has also initiated a multiple ascending dose (MAD) trial targeting early Alzheimer’s patients, with initial tau imaging results anticipated by the second half of 2026. This program is part of Voyager's broader strategy to advance treatments targeting tau pathology in Alzheimer's disease. VY7523's promising preclinical results support its potential as a leading treatment option in this space.
Read more →VYGRVOYAGER ALERT: Bragar Eagel & Squire, P.C. is Investigating Voyager Therapeutics, Inc. on Behalf of Voyager Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating Voyager Therapeutics, Inc. on behalf of stockholders due to potential violations of federal securities laws and unlawful business practices. The investigation follows Voyager's recent announcement about issues with its gene therapy program for SOD1 ALS, specifically concerns regarding the siRNA payload component of VY9323. As a result of this announcement, Voyager's stock price fell by over 20%, prompting the law firm's involvement to protect investor rights. Voyager now does not expect to file an IND application for VY9323 as initially planned.
Read more →VYGRVoyager Therapeutics to Present at Multiple Upcoming Investor Conferences
Voyager Therapeutics, Inc. has announced its participation in several upcoming investor conferences, including the TD Cowen 45th Annual Health Care Conference and the Stifel 2025 Virtual CNS Forum. Presentations are scheduled for March 3 and March 19, 2025, respectively. The company emphasizes its focus on neurogenetic therapies targeting neurological diseases, supported by its TRACER™ AAV capsid discovery platform. Webcasts of each presentation will be available for interested investors.
Read more →VYGR▼ -21%on this news
Voyager Provides Update on SOD1 ALS Gene Therapy Program
Voyager Therapeutics has decided to explore alternative payloads for its SOD1 ALS gene therapy program following preclinical data showing the current candidate may not meet the desired product profile. Consequently, the timeline for the IND application for VY9323 has been delayed, which also extends the cash runway for the company into mid-2027. Despite these setbacks, Voyager's other programs are expected to remain on track, with IND filings anticipated in 2025 for GBA1 and Friedreich’s ataxia therapies, and encouraging results from their TRACER capsids.
Read more →VYGRVoyager to Present at Oppenheimer 25th Annual Healthcare Life Sciences Conference
Voyager Therapeutics, Inc. announced its participation in a fireside chat at the Oppenheimer 25th Annual Healthcare Life Sciences Conference scheduled for February 11, 2025. The event will showcase the company's dedication to advancing neurogenetic medicines aimed at curing neurological diseases. A live webcast of the presentation will be available for investors, and a recorded version will be archived on the company's website for at least 30 days. Voyager's pipeline includes treatments for Alzheimer's, ALS, Parkinson's disease, among others.
Read more →VYGRVoyager Selects Tau Silencing Gene Therapy Development Candidate for Alzheimer’s Disease
Voyager Therapeutics has selected VY1706 as its lead candidate for tau silencing gene therapy targeting Alzheimer's disease. In non-human primate studies, VY1706 showed impressive reductions in tau levels, which are associated with Alzheimer's progression. The company plans to file an IND application with the FDA and a CTA with Health Canada by 2026. The development leverages the TRACER capsid platform, enhancing the therapy's effectiveness in crossing the blood-brain barrier. Voyager expresses commitment to advancing its tau-targeted treatments based on encouraging preliminary data.
Read more →VYGRVoyager Reports Third Quarter 2024 Financial and Operating Results -Enrollment and dosing complete in single ascending dose clinical trial of anti-tau antibody VY7523 for Alzheimer's; on track to generate top-line data H
Voyager Therapeutics reported its third quarter 2024 financial results, highlighting the completion of enrollment and dosing in a clinical trial for its anti-tau antibody VY7523 aimed at Alzheimer's disease. The company anticipates generating top-line data in the first half of 2025, bolstered by encouraging third-party clinical data suggesting that targeting tau may provide significant clinical benefits. Voyager is also progressing towards IND filings for multiple CNS gene therapies in 2025 and maintains a robust cash position to support its endeavors through 2027.
Read more →VYGRVoyager Therapeutics Announces Third Quarter 2024 Conference Call and Webcast
Voyager Therapeutics, Inc. has announced that it will report its third quarter financial and operating results on November 12, 2024, after market close. A conference call and webcast will follow at 4:30 p.m. ET, allowing stakeholders to listen and engage in discussions. The company is focused on developing treatments for neurological diseases using its TRACER™ platform. A replay of the call will be available for at least 30 days post-event.
Read more →VYGRVoyager Advances Collaboration with Neurocrine; Third Gene Therapy Development Candidate Selected
Voyager Therapeutics has advanced its collaboration with Neurocrine Biosciences by selecting a new gene therapy development candidate targeting a neurological disease. This selection triggers a $3 million milestone payment and positions Voyager for additional royalties and milestone payments as the program develops. The collaboration is part of a broader strategic agreement that includes other programs for neurological diseases, aiming to leverage Voyager's innovative TRACER capsid platform for gene therapy applications.
Read more →VYGRVoyager Enters into License for Next-Generation Capsid, Bringing Partnered Portfolio of TRACER-Enabled Gene Therapies to 14
Voyager Therapeutics has entered into a licensing agreement with Novartis for a novel capsid derived from its TRACER platform to be used in a gene therapy targeting an undisclosed rare neurologic disease. This agreement enhances Voyager's partnership portfolio to 14 gene therapies, including prominent programs for Huntington's disease and spinal muscular atrophy. Voyager will receive an upfront payment of $15 million and has the potential to earn up to $305 million in further milestone payments, alongside royalties. This development underscores the validation and success of Voyager's gene therapy innovations.
Read more →VYGRVoyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Voyager Therapeutics announced the approval of inducement grants for a newly hired employee, including a non-qualified stock option and restricted stock units. The awards, which facilitate recruitment, comply with Nasdaq Listing Rule 5635(c)(4), and the stock options have a ten-year term at a set exercise price. Vesting for the awards is contingent on the employee's continued service with the company. This move reflects Voyager's commitment to attracting talent as it continues its mission in neurogenetic medicines.
Read more →VYGR▼ -14%on this news
Voyager Therapeutics to Present at Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase
Voyager Therapeutics, a biotechnology firm focused on neurogenetic medicines, has announced its participation in the Canaccord Genuity 44th Annual Growth Conference on August 14, 2024. During the event, a fireside chat will be held, offering insights into the company's initiatives and future directions. Voyager aims to address neurological diseases through its innovative TRACER™ AAV capsid discovery platform, with programs targeting conditions such as Alzheimer's disease and ALS. Investors and media representatives are provided with contact information for further inquiries.
Read more →VYGRVoyager Therapeutics Reports Second Quarter 2024 Financial and Operating Results - Top-line safety and pharmacokinetic data expected in H1 2025 from recently initiated single ascending dose trial of anti-tau antibody for
Voyager Therapeutics has reported its second quarter 2024 financial and operational results, highlighting progress in its neuroscience-focused pipeline. The company announced a new trial for an anti-tau antibody for Alzheimer's disease, with key data expected in the first half of 2025. Additionally, Voyager has a robust cash position of $371 million, enabling it to fund development activities through 2027, and anticipates three IND filings in 2025 for its gene therapy programs. The appointment of Dr. Nathan Jorgensen as Chief Financial Officer further strengthens the company's leadership team.
Read more →VYGRVoyager Therapeutics Announces Second Quarter 2024 Conference Call and Webcast
Voyager Therapeutics, Inc. has announced that it will release its second quarter 2024 financial and operational results on August 6, 2024, after market close. Following the results, the company will host a conference call and webcast for investors to discuss these findings. The call is scheduled for 4:30 p.m. ET, and both telephone participation and a live webcast will be available. Voyager is focused on developing therapies for neurological diseases and has a variety of programs in its pipeline.
Read more →VYGRVoyager Therapeutics to Present at Multiple Virtual Investor Conferences
Voyager Therapeutics, Inc. (Nasdaq: VYGR) announced its participation in two upcoming virtual investor conferences, aiming to engage with the investment community. The conferences are the TD Cowen Genetic Medicines & RNA Summit and the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference, scheduled for June 20 and June 27, 2024, respectively. Webcasts of these presentations will be available on the company's website for at least 30 days following the events. Voyager is focused on leveraging human genetics to develop treatments for neurological diseases and has a robust pipeline in this area.
Read more →VYGRVoyager Therapeutics Announces Appointment of Nathan Jorgensen as Chief Financial Officer
Voyager Therapeutics has announced the appointment of Nathan Jorgensen as the new Chief Financial Officer, effective July 8, 2024. Jorgensen brings extensive experience in finance and neuroscience, having previously served as CFO for Vor Biopharma and held various roles in investment banking and healthcare investing. The CEO of Voyager expressed confidence in Jorgensen's ability to drive value creation and advance their pipeline of neurogenetic medicines. This strategic appointment aims to enhance Voyager's efforts in addressing significant challenges in the field of neurology.
Read more →VYGRVoyager Therapeutics Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 for the Treatment of Alzheimer’s Disease
Voyager Therapeutics announced the dosing of the first participants in a Phase 1a trial for VY-TAU01, an anti-tau antibody aimed at treating Alzheimer's disease. This double-blind, placebo-controlled study is set to evaluate the safety and pharmacokinetics of the treatment in healthy volunteers, with future studies planned for early Alzheimer's patients. The trial's outcome may influence later stages of development and is viewed as a critical milestone for the company, as Alzheimer’s disease continues to present substantial challenges and unmet needs in patient care.
Read more →VYGRVoyager Therapeutics Reports First Quarter 2024 Financial and Operating Results - Company announces clearance of IND application with FDA for anti-tau antibody VY-TAU01 for the treatment of Alzheimer's disease; expect to
Voyager Therapeutics announced its first quarter 2024 financial results, highlighting the clearance of an IND application for its anti-tau antibody, VY-TAU01, aimed at treating Alzheimer's disease. The company is set to begin a single ascending dose trial in the coming weeks. Additionally, Voyager's gene therapy candidates for GBA1 and Friedreich's Ataxia are progressing, with expectations for IND filings in 2025. With a robust cash position of approximately $400 million, Voyager anticipates sufficient funding to support its clinical objectives into 2027.
Read more →VYGRVoyager Therapeutics Presents Data for Second-Generation, TRACER™-Generated Capsids and CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting
Voyager Therapeutics presented promising data regarding its second-generation TRACER capsids and CNS gene therapy programs at the ASGCT 27th Annual Meeting. These capsids demonstrated enhanced delivery across the blood-brain barrier and substantial transgene expression in various brain regions. Notably, an ALS treatment candidate showed significant reductions in SOD1 mRNA in animal models. Voyager anticipates initiating IND filings for its gene therapy programs by 2025, showcasing the potential for innovative neurogenetic treatments.
Read more →VYGRVoyager Therapeutics Announces First Quarter 2024 Conference Call and Webcast
Voyager Therapeutics, Inc. announced it will release its first quarter 2024 financial and operating results on May 13, 2024. A conference call and webcast will follow at 4:30 p.m. ET to discuss these results. Investors can join the call via telephone or a live webcast available on the company's website. More information on their drug pipeline focusing on neurological diseases is also presented.
Read more →VYGRVoyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting
Voyager Therapeutics will showcase extensive data relating to its TRACER capsid discovery platform at the upcoming ASGCT annual meeting. This platform supports several gene therapy programs aimed at treating central nervous system diseases, with three programs having development candidates ready for potential clinical trials in the coming year. Presentations will include findings on enhanced brain tropism and preclinical results for Alzheimer's and ALS therapies, among other topics. The company emphasizes the promising capabilities of its novel IV-delivered capsids, indicating significant advances in its gene therapies.
Read more →VYGRVoyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment
Voyager Therapeutics has selected a lead candidate for its GBA1 gene therapy program in partnership with Neurocrine Biosciences, focusing on Parkinson's disease. This milestone triggers a $3 million payment to Voyager, expected in Q2 2024. The collaboration anticipates filing for an Investigational New Drug application in 2025, with additional development milestone opportunities amounting to $1.5 billion. The program utilizes Voyager's TRACER capsid technology aimed at enhanced delivery to the central nervous system.
Read more →VYGRVoyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical Officer
Voyager Therapeutics announced the appointment of Toby Ferguson as Chief Medical Officer, effective March 25, 2024. Ferguson, who has extensive experience in neuromuscular development from his previous role at Biogen, will help advance Voyager's AAV gene therapy programs and the anticipated IND filing for VY-TAU01 targeting Alzheimer's disease. The company aims to file an IND each year through 2026. CEO Alfred W. Sandrock Jr. expressed confidence in Ferguson's capabilities to enhance clinical program design, while acknowledging the inherent uncertainties in accelerating their research efforts.
Read more →VYGRVoyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results - Company had approximately $431 million in pro-forma cash as of
Voyager Therapeutics reported robust financial results for Q4 and the full year 2023, with approximately $431 million in pro-forma cash. This financial stability, bolstered by recent collaborations with Novartis and Neurocrine, is expected to support the advancement of multiple clinical candidates through at least 2027. The company anticipates significant developmental milestones, including advancing their anti-tau antibody program, VY-TAU01, towards IND by mid-2024. Additionally, Voyager's TRACER platform aims to enhance gene therapy effectiveness for CNS diseases.
Read more →VYGR▲ +5.6%on this newsshared move
Voyager Therapeutics Announces Selection of Gene Therapy Development Candidate for Friedreich’s Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment
Voyager Therapeutics has announced the selection of a lead development candidate in collaboration with Neurocrine Biosciences for its Friedreich's ataxia program. This selection has triggered a $5 million milestone payment, which is expected in early 2024. The candidate utilizes a novel capsid from Voyager's TRACER platform and aims to advance into clinical trials by 2025. The partnership potentially opens up pathways for substantial future financial incentives, including additional milestone payments and royalties. Despite recent advancements, Friedreich's ataxia remains a complex and fatal condition, highlighting the need for innovative therapeutic solutions.
Read more →VYGRVoyager Therapeutics Announces Fourth Quarter 2023 Conference Call and Webcast
Voyager Therapeutics, Inc. is set to report its fourth quarter 2023 financial and operational results on February 28, 2024. Following the announcement, a conference call and webcast will be held at 4:30 p.m. ET for discussion of these results. The event underscores the company's commitment to transparency and engagement with its investors. Additionally, Voyager is focused on neurogenetic medicines, with a pipeline addressing major neurological diseases.
Read more →VYGRVoyager Therapeutics Reports Robust Preclinical Activity in Tau Silencing Gene Therapy Program for Alzheimer’s Disease and Advances Program into Late Research
Voyager Therapeutics has reported promising preclinical results for its tau silencing gene therapy program targeting Alzheimer's disease. Data indicate that the therapy significantly reduces tau levels in animal models, leading Voyager to advance the program to late research stages with plans to file for investigational new drug status by 2026. Additionally, the lead antibody candidate, VY-TAU01, displayed favorable pharmacokinetics and was well-tolerated in non-human primates. The findings will be presented at the upcoming 2024 International Conference on Alzheimer’s and Parkinson’s Diseases.
Read more →VYGRVoyager Therapeutics to Present at the Oppenheimer Annual Life Sciences Conference
Voyager Therapeutics, Inc. announced that its Chief Financial Officer, Peter Pfreundschuh, will present at the Oppenheimer Annual Life Sciences Conference on February 14, 2024. This presentation aims to share insights on the company's advancement in neurogenetic medicines. A webcast will be available for stakeholders and will remain accessible for 30 days after the event. Voyager Therapeutics is focused on developing therapies for neurological diseases, leveraging their proprietary technology.
Read more →VYGRVoyager Therapeutics Announces Pricing of Public Offering LEXINGTON, Mass. , JANUARY 4, 2024 - Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today annou
Voyager Therapeutics, Inc. announced the pricing of a public offering, intending to sell 7,777,778 shares at $9.00 per share. The offering aims to raise around $100 million to advance its clinical programs, particularly in Alzheimer's disease and amyotrophic lateral sclerosis (ALS). With the closure anticipated on January 9, 2024, this funding is also supported by an upcoming larger payment from Novartis. The offering includes a provision for underwriters to purchase additional shares, expanding the potential funding.
Read more →VYGR▼ -18.4%on this newsshared move
Voyager Therapeutics Announces Pricing of Public Offering
Voyager Therapeutics announced the pricing of an underwritten public offering of 7,777,778 shares at $9.00 per share, aiming for gross proceeds of approximately $100 million. The offering intends to support the advancement of its neurogenetic medicines, particularly programs for Alzheimer’s disease and amyotrophic lateral sclerosis. The closing of the offering is projected for January 9, 2024, contingent on customary closing conditions. Voyager's strategic collaboration with Novartis also contributes to its funding strategy.
Read more →VYGRVoyager Therapeutics Announces Proposed Public Offering
Voyager Therapeutics has announced a proposed public offering of $100 million in common stock to fund the development of its neurogenetic medicines. The company plans to use the net proceeds from this offering, along with existing cash and collaborations, to advance its pipeline, particularly for Alzheimer’s disease and amyotrophic lateral sclerosis. Citigroup and Guggenheim Securities are leading the offering, which is subject to market conditions and final regulatory approval.
Read more →VYGR▲ +19.7%on this newsshared move
Voyager Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Voyager Therapeutics, Inc. (Nasdaq: VYGR) has announced that its CEO, Alfred W. Sandrock, Jr., will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on January 10, 2024. This event is a significant platform for showcasing Voyager's advancements in neurogenetic medicines. The company focuses on neurological disease treatments and operates using its TRACER™ AAV capsid discovery platform to facilitate drug development. Interested parties can access a live webcast of the presentation through the company's investor webpage.
Read more →VYGR▲ +6.6%on this news· ran to +28% by day 1shared move
Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Advance Novel Gene Therapies
Voyager Therapeutics announced a strategic collaboration and capsid license agreement with Novartis Pharmaceuticals to develop gene therapies for Huntington's disease and spinal muscular atrophy. Under the agreement, Voyager will receive $100 million upfront and has the opportunity to earn up to $1.2 billion in milestone payments. Novartis will gain exclusive access to Voyager's TRACER capsids, facilitating advancements in treatments for neurological conditions. The partnership aims to leverage both companies' strengths in gene therapy development.
Read more →VYGRVoyager Therapeutics Announces Selection of Development Candidate for SOD1 Amyotrophic Lateral Sclerosis Gene Therapy Program
Voyager Therapeutics has announced the selection of a lead development candidate for its gene therapy program targeting SOD1 amyotrophic lateral sclerosis (ALS). The company plans to file an Investigational New Drug (IND) application by mid-2025, marking a significant step forward in their research efforts. This development highlights Voyager's commitment to advancing gene therapy in neurology.
Read more →VYGRVoyager Therapeutics Announces Selection of Development Candidate for SOD1 Amyotrophic Lateral Sclerosis Gene Therapy Program - IND filing expected in mid-2025 - LEXINGTON, Mass. , DECEMBER 6, 2023 - Voyager Therapeutics
Voyager Therapeutics has selected a lead development candidate for its SOD1 amyotrophic lateral sclerosis (ALS) gene therapy program, anticipating an IND filing by mid-2025. The new candidate showed a 73% reduction of SOD1 in non-human primates after a single intravenous dose, suggesting robust efficacy. Voyager's approach utilizes a novel TRACER capsid to facilitate blood-brain barrier penetration and achieve effective transduction in relevant cell types. The company plans to present additional data at a future scientific conference to bolster its program's potential.
Read more →VYGR▲ +5.1%on this news
Voyager Therapeutics Reports Third Quarter 2023 Financial and Operating Results
Voyager Therapeutics has reported its third quarter 2023 financial results, highlighting the initiation of GLP toxicology studies for its VY-TAU01 anti-tau antibody aimed at Alzheimer's disease. The company anticipates filing an Investigational New Drug (IND) application in the first half of 2024. Additionally, the SOD1 ALS gene therapy program is on track for development candidate selection by the end of the year.
Read more →VYGRVoyager Therapeutics Reports Third Quarter 2023 Financial and Operating Results - GLP toxicology studies initiated for VY-TAU01 anti-tau antibody for Alzheimer's disease to enable anticipated 1H 2024 IND filing - - SOD1
Voyager Therapeutics reported its financial and operating results for the third quarter of 2023, highlighting key advancements in its gene therapy programs. The company initiated GLP toxicology studies for the VY-TAU01 anti-tau antibody, aiming for an IND filing in the first half of 2024. Additionally, they anticipate finalizing a development candidate for their SOD1 ALS gene therapy program by year-end. Voyager also maintains a strong financial outlook, expecting its resources to be adequate to cover operating expenses and capital requirements into mid-2025.
Read more →VYGRVoyager Therapeutics Announces Third Quarter 2023 Conference Call and Webcast
Voyager Therapeutics, Inc. has announced it will release its third quarter 2023 financial and operating results after market close on November 6, 2023. Following the release, the company will host a conference call and webcast to discuss these results. Interested participants can register in advance to join the call or access a live webcast on Voyager's website. Voyager is focused on advancing gene therapy for neurological diseases and has established multiple partnerships to enhance its research capabilities.
Read more →VYGRVoyager Therapeutics to Present at the Chardan Genetic Medicines Conference
Voyager Therapeutics announced that its CEO, Alfred W. Sandrock, Jr., will present at the Chardan 7th Annual Genetic Medicines Conference in New York on October 2, 2023. This event showcases the company's dedication to advancements in gene therapy and neurology. Voyager is noted for its TRACER™ capsid discovery platform, which aims to improve delivery mechanisms crucial for effective treatment.
Read more →VYGRVoyager Therapeutics to Participate in Upcoming Investor Conferences
Voyager Therapeutics will participate in two upcoming investor conferences: the Wells Fargo Health Care Conference on September 6, 2023, and the Baird Global Healthcare Conference on September 12, 2023. These events will feature management in fireside chats, providing insights into the company's strategies and developments. Voyager is focused on advancing gene therapy and neurology through its TRACER™ platform, which aims to improve therapeutic delivery methods. The company is engaged in several partnerships with major pharmaceutical firms and has a pipeline targeting central nervous system diseases.
Read more →VYGRVoyager Therapeutics Announces Appointment of Beth Shafer as Chief Business Officer
Voyager Therapeutics has appointed Beth Shafer as its new Chief Business Officer. Shafer brings over 15 years of experience in business development, particularly in neurology, having held significant roles at companies including Takeda, Novartis, and Roche. CEO Alfred W. Sandrock, Jr. highlighted Shafer's potential to optimize business opportunities for the company. Voyager continues to focus on advancing its gene therapy initiatives, particularly through its TRACER capsid platform, which has captured substantial interest from third parties.
Read more →VYGRVoyager Therapeutics Reports Second Quarter 2023 Financial and Operating Results
Voyager Therapeutics reported its second quarter 2023 financial and operating results, highlighting the introduction of a new vectorized anti-Aβ antibody gene therapy initiative aimed at Alzheimer's disease. The company also executed a license agreement with Sangamo for a treatment targeting prion disease. Additionally, they presented promising preclinical results demonstrating improved brain transduction from IV administration.
Read more →VYGRVoyager Therapeutics Reports Second Quarter 2023 Financial and Operating Results - Introduced new vectorized anti-A antibody gene therapy research initiative, expanding Alzheimer's disease portfolio - - Executed license
Voyager Therapeutics reported its second quarter 2023 financial results, highlighting a new vectorized anti-A antibody gene therapy initiative aimed at Alzheimer's disease. The company also executed a license agreement with Sangamo for a treatment related to prion diseases and showcased promising preclinical findings regarding their TRACER capsids at ASGCT 2023. Voyager expects their financial reserves to support operations through 2025 while advancing a robust pipeline in gene therapies for central nervous system disorders.
Read more →VYGRVoyager Therapeutics to Present at the Canaccord Genuity Growth Conference
Voyager Therapeutics, Inc. (Nasdaq: VYGR) will be represented by its Chief Scientific Officer Todd Carter and Chief Financial Officer Peter Pfreundschuh at the Canaccord Genuity 43rd Annual Growth Conference on August 10, 2023. The biotechnology company specializes in gene therapy and neurology, working to overcome delivery challenges in these fields. The event will include a fireside chat that will be accessible via the company's website, and a replay will be available for 30 days post-event.
Read more →VYGRVoyager Therapeutics Announces Second Quarter 2023 Conference Call and Webcast
Voyager Therapeutics, Inc. has announced that it will report its second quarter 2023 financial and operating results before the market opens on August 3, 2023. Following the release, the company will hold a conference call and webcast at 8:30 a.m. ET to discuss these results. Voyager is focused on advancing gene therapy solutions, leveraging its TRACER AAV capsid discovery platform for enhanced delivery in treating neurological diseases. The event will include opportunities for participants to join via telephone or through a live webcast.
Read more →VYGRVoyager Therapeutics Announces Appointment of Jacquelyn Fahey Sandell as Chief Legal Officer
Voyager Therapeutics has appointed Jacquelyn Fahey Sandell as Chief Legal Officer. With over 25 years of legal experience, she has held significant roles in various biotech companies, notably at Jounce Therapeutics. Fahey Sandell's expertise will contribute to Voyager's efforts in developing genetic medicines for neurological disorders. This strategic hire is seen as a valuable addition to Voyager's senior leadership as they aim to enhance their capabilities in gene therapy and neurology.
Read more →VYGRVoyager Therapeutics to Present at the Jefferies Healthcare Conference
Voyager Therapeutics, a biotechnology company focused on gene therapy and neurology, will present at the Jefferies Healthcare Conference on June 8, 2023. CEO Alfred W. Sandrock, Jr. will lead the presentation, which can be accessed via a webcast. The company is recognized for its TRACER AAV capsid discovery platform, aiming to enhance delivery and efficacy in gene therapy. Voyager's pipeline includes programs targeting conditions such as Alzheimer's disease, ALS, Parkinson's disease, and Friedreich’s Ataxia.
Read more →VYGRVoyager Therapeutics Presents Robust, Multi-Species Results from Preclinical Studies of IV-Delivered, TRACER™-Generated Novel Capsids at the ASGCT 26th Annual Meeting
Voyager Therapeutics presented promising preclinical data on its TRACER platform at the ASGCT 2023 Annual Meeting. The research highlighted how novel capsids improved blood-brain barrier penetration and transgene expression in multiple brain regions in non-human primates and mice. Additionally, the findings suggest these capsids may successfully translate into human clinical trials, potentially advancing gene therapies for neurologic diseases. The TRACER platform's ability to generate diverse capsids indicates a significant leap in gene therapy delivery systems.
Read more →VYGR▲ +29.5%on this news
Voyager Therapeutics Reports First Quarter 2023 Financial and Operating Results - Neurocrine Biosciences strategic collaboration and Novartis license option exercise demonstrate Voyager pipeline and platform value and st
Voyager Therapeutics reported its first-quarter 2023 financial and operational results, emphasizing a strong balance sheet bolstered by strategic collaborations with Neurocrine Biosciences and Novartis. The company highlighted advancements in its Alzheimer's disease franchise, including the selection of a lead candidate for an anti-tau antibody program and plans for an IND submission in the first half of 2024. Voyager also announced successful data presentations validating its capsid technology's effectiveness in penetrating the blood-brain barrier and enhancing central nervous system targeting.
Read more →VYGR▲ +29.5%on this news
Voyager Therapeutics Announces Appointment of George Scangos, Ph.D., to Board of Directors
Voyager Therapeutics has appointed George Scangos, Ph.D., to its Board of Directors, effective immediately. Scangos, a seasoned executive with vast experience in biotechnology, has previously led prominent companies including Biogen and Exelixis. His appointment is expected to provide valuable insight into overcoming the challenges facing gene therapy and neurology. Scangos has expressed enthusiasm for Voyager's innovative approaches and potential advancements in neurotherapeutics.
Read more →VYGRVoyager Therapeutics Announces First Quarter 2023 Conference Call and Webcast
Voyager Therapeutics, Inc. has announced that it will report its first quarter 2023 financial and operational results on May 9, 2023. A conference call and webcast will be held at 8:30 a.m. ET on the same day to discuss these results. The company is focused on advancements in gene therapy and neurology, leveraging its TRACERTM AAV capsid discovery platform to improve drug delivery. Voyager's collaborations and pipeline target significant neurological diseases, promising potential developments in the field.
Read more →VYGRVoyager Therapeutics Announces Multiple Data Presentations at the American Society of Gene and Cell Therapy 26th Annual Meeting
Voyager Therapeutics has announced that it will present seven data presentations at the upcoming ASGCT 26th Annual Meeting, showcasing advancements from its TRACER AAV capsid discovery platform. This platform aims to improve gene therapy efficacy by enhancing blood-brain barrier penetration and CNS targeting. Voyager is also expanding its partnerships with notable companies like Pfizer, which could accelerate their ongoing projects. However, the company acknowledges risks related to uncertainties in presentation acceptance and delivery at the conference.
Read more →VYGRVoyager Therapeutics Presents New Data Supporting Tau Antibody Program for Alzheimer’s Disease and GBA1 Gene Therapy Program for Parkinson’s Disease at the AD/PD™ Conference
Voyager Therapeutics presented promising new data regarding its anti-tau antibody program for Alzheimer's disease and GBA1 gene therapy program for Parkinson's disease at the AD/PD Conference. The data supports the advancement of VY-TAU01 as a lead development candidate, with an IND filing anticipated in early 2024. Additionally, the GBA1 gene therapy demonstrated effectiveness in a mouse model, indicating potential for treating Parkinson's disease and related conditions. Both programs showcase Voyager's commitment to addressing significant neurological disorders through innovative therapies.
Read more →VYGR▼ -7.8%on this news
Voyager Therapeutics Reports Fourth Quarter and Full Year 2022 Financial and Operating Results - Transformational progress in 2022 marked by reprioritization of high-value neurology pipeline and validation of TRACER TM n
Voyager Therapeutics reported its fourth quarter and full year 2022 results, highlighting significant progress in its neurology pipeline, including a focus on novel gene therapies for CNS diseases. The company has secured key partnerships with Neurocrine, Pfizer, and Novartis, bolstering its financial outlook and future research capabilities. Upcoming milestones include the expected IND filings for Alzheimer's disease and ALS programs in 2024, along with new initiatives in nanocarrier technologies. Overall, the company emphasizes its commitment to addressing critical unmet needs in neurology.
Read more →VYGR▲ +8.9%on this newsshared move
Voyager Therapeutics to Receive $25 Million Payment for License of Next-Generation AAV Capsids for Multiple Neurologic Disease Targets
Voyager Therapeutics announced that Novartis AG has exercised options to license novel AAV capsids for two undisclosed neurologic disease targets, leading to an additional $25 million payment for Voyager. This agreement potentially includes up to $600 million in future milestone payments and tiered royalties on product sales. Furthermore, Novartis retains the right to expand the agreement to include additional targets in the next 18 months, enhancing Voyager's partnerships and financial stability in gene therapy development. However, Novartis declined to license one CNS target, which has returned to Voyager.
Read more →VYGRVoyager Therapeutics Announces Fourth Quarter and Full Year 2022 Conference Call and Webcast
Voyager Therapeutics, Inc. has announced that it will report its fourth quarter and full year 2022 financial results before the market opens on March 7, 2023. A live conference call and webcast will take place at 8:30 a.m. ET to discuss these results. The company is recognized for its work in gene therapy and neurology, aiming to tackle challenges in these fields. Voyager is leveraging its TRACERTM AAV capsid discovery platform to enhance delivery methods, which may significantly impact its pipeline programs.
Read more →VYGRVoyager Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
Voyager Therapeutics, Inc. will present at the 41st Annual J.P. Morgan Healthcare Conference, highlighting its commitment to gene therapy and neurology advancements. CEO Alfred W. Sandrock, Jr. will deliver the presentation on January 12, 2023. The company focuses on addressing delivery challenges in gene therapy through its TRACER™ AAV capsid discovery platform, which has yielded novel capsids with enhanced target delivery capabilities. Voyager maintains collaborations with prominent pharmaceutical companies, indicating a robust pipeline in neurodegenerative diseases.
Read more →VYGR▲ +9.6%on this news
Voyager Therapeutics Reports Third Quarter 2022 Financial and Operating Results - Voyager's TRACER TM capsid platform validated by Pfizer option exercise - - Data characterizing a novel receptor and demonstrating low-dos
Voyager Therapeutics Reports Third Quarter 2022 Financial and Operating Results - Voyager's TRACERTM capsid platform validated by Pfizer option exercise - - Data characterizing a novel receptor and demonstrating low-dose potential further validate TRACER - - Pipeline programs
Read more →VYGRVoyager Therapeutics Announces Third Quarter 2022 Conference Call and Webcast
CAMBRIDGE, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, today announced it will report third quarter 2022 f
Read more →VYGR▲ +5.1%on this news
Voyager Therapeutics Presents Data Characterizing a Novel CNS Receptor and Demonstrating the Low-Dose Potential of TRACER™ Generated Capsid Families
- Data presented at European Society of Gene & Cell Therapy (ESGCT) Congress 2022 - - Receptor findings support potential for human translation of Voyager’s capsids and may help overcome barriers to CNS drug delivery - CAMBRIDGE, Mass., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Voyager
Read more →VYGR▲ +17.4%on this news
Voyager Therapeutics Announces Pfizer License of Next-Generation AAV Capsid for Rare Neurologic Disease Target
Option exercise triggers $10 million payment to Voyager, further validating the potential of the TRACER capsid platform Voyager eligible for up to $290 million in associated development, regulatory, and commercial milestones, plus tiered royalties CAMBRIDGE, Mass., Oct. 04, 202
Read more →VYGRVoyager Therapeutics Announces Data Presentations at the 29th Annual Congress of the European Society of Gene & Cell Therapy
CAMBRIDGE, Mass., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, today announced that it will present three posters
Read more →VYGR▲ +7.6%on this news
Voyager Therapeutics Appoints Peter Pfreundschuh as CFO; Todd Carter, Ph.D., as Chief Scientific Officer; and Trista Morrison as SVP Corporate Affairs
CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, today announced the appointment of Peter Pfreundsc
Read more →VYGR▲ +5.7%on this news
Voyager Therapeutics Prioritizes Pipeline and Reports Second Quarter 2022 Financial and Operating Results Pipeline prioritizes tau antibody for Alzheimer s disease and gene therapies for GBA1 Parkinson s disease and SOD1
Voyager Therapeutics Prioritizes Pipeline and Reports Second Quarter 2022 Financial and Operating Results Pipeline prioritizes tau antibody for Alzheimer's disease and gene therapies for GBA1 Parkinson's disease and SOD1-ALS, each program employing efficient paths to human proof
Read more →VYGR▲ +6.3%on this newsshared move
Voyager Therapeutics Presents New Data Demonstrating Novel Candidate Therapeutic Antibodies Reduced Tau Pathology in Multiple Preclinical Models
Novel passive antibodies bind to paired helical filamentous tau and inhibit propagation of pathological tau Vectorized antibody demonstrates durable CNS expression more than six months post-dose Research presented at the Alzheimer’s Association International Conference CAMBRID
Read more →VYGRVoyager Therapeutics to Present Second Quarter 2022 Results and Corporate Update
CAMBRIDGE, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, will report second quarter 2022 financial and opera
Read more →VYGRVoyager Therapeutics Appoints Catherine J. Mackey, Ph.D. to its Board of Directors
CAMBRIDGE, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, today announced the appointment of Catherine J. Mackey, Ph.D. to its
Read more →VYGRVoyager Therapeutics’ TRACER™ Capsids Demonstrate Enhanced CNS Transduction Across Species; New Preclinical Results Bolster GBA1, Tau, SOD1 ALS Gene Therapy Programs
VCAP-102 capsid achieved respective 60-fold and 50-fold improvements in brain transduction in non-human primates and mice compared to conventional AAV9 capsids with IV dosing Data demonstrate potential of multiple TRACER capsids to target CNS disorders, including certain disease
Read more →VYGRVoyager Therapeutics to Present Preclinical Data from its Vectorized anti-HER2 Antibody Program and a Novel AAV5-Derived TRACER™ Capsid at the 25th American Society of Gene and Cell Therapy Annual Meeting
Single dose of TRACER AAV vector encoding anti-HER2 antibody reduced CNS tumor burden and extended survival across multiple mouse models of breast cancer brain metastasis Novel AAV5-derived capsid improved transduction in multiple CNS regions and cell types in non-human primates
Read more →VYGRVoyager Therapeutics Reports First Quarter 2022 Financial and Operating Results Company to present new data at the American Society for Gene and Cell Therapy (ASGCT) Annual Meeting highlighting cross-species translatabil
Voyager Therapeutics Reports First Quarter 2022 Financial and Operating Results Company to present new data at the American Society for Gene and Cell Therapy (ASGCT) Annual Meeting highlighting cross-species translatability and CNS tropisms of novel TRACERTM AAV9 and AAV5-derive
Read more →VYGR▲ +8.1%on this news· ran to -21% by day 3shared move
Voyager Therapeutics Announces Multiple Data Presentations at the American Society of Gene and Cell Therapy 2022 Annual Meeting
CAMBRIDGE, Mass., May 03, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, today announced nine data presentations at the upcoming American Soci
Read more →VYGRVoyager Therapeutics Appoints Alfred W. Sandrock, Jr., M.D., Ph.D., as Chief Executive Officer
CAMBRIDGE, Mass., March 22, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, today announced the appointment of Alfred W. Sandrock, Jr., M.D., P
Read more →VYGR▲ +33.3%on this news· ran to +60% by day 1
Voyager Therapeutics Announces License Option Agreement with Novartis for Target-Specific Access to Next-Generation TRACER™ AAV Capsids for Gene Therapy Programs
Voyager receives $54 million upfront with potential option exercise fees and milestone payments of up to $1.7 billion plus product sales-based royalties Novartis receives target-specific access to Voyager’s novel TRACER AAV capsids for potential use with three CNS targets plus o
Read more →VYGR▲ +33.3%on this news· ran to +60% by day 1
Voyager Therapeutics Reports Fourth Quarter and Full Year 2021 Financial and Operating Results License option agreement with Novartis for target-specific access to TRACER TM next-generation AAV capsids for potential use
Voyager Therapeutics Reports Fourth Quarter and Full Year 2021 Financial and Operating Results License option agreement with Novartis for target-specific access to TRACERTM next-generation AAV capsids for potential use with three CNS targets plus options to access capsids for tw
Read more →VYGRVoyager Therapeutics Announces Positive Preclinical Data from New Vectorized anti-HER2 Antibody Program at the 26th Society for Neuro-Oncology Annual Meeting
Novel intravenous (IV) vectorized antibody approach designed to activate innate immune system, destroy metastatic breast cancer tumors, and inhibit tumor progression in CNS Proprietary TRACER™ capsid screening technology enables broad expression of vectorized antibody in mouse b
Read more →VYGRVoyager Therapeutics to Present Preclinical Data from Vectorized Antibody Program at the 26th Society for Neuro-Oncology Annual Meeting
CAMBRIDGE, Mass., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) platform technologies, today announced it will present preclinical data from
Read more →VYGRVoyager Therapeutics Reports Third Quarter 2021 Financial and Operating Results License option agreement with Pfizer provides Voyager $30M up front and up to $600M in potential exercise fees and milestones payments plus
Voyager Therapeutics Reports Third Quarter 2021 Financial and Operating Results License option agreement with Pfizer provides Voyager $30M up front and up to $600M in potential exercise fees and milestones payments plus royalties in exchange for access to TRACER novel capsids fo
Read more →VYGR▼ -7.2%on this news
Voyager Therapeutics Presents Positive Preclinical Data Supporting CNS-Directed GBA1 Gene Therapy at Virtual Congress of the European Society of Gene and Cell Therapy
CAMBRIDGE, Mass., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) platform technologies, today announced the presentation of preclinical data d
Read more →VYGR▲ +6%on this newsshared move
Voyager Therapeutics Transforms Pipeline and Increases Investment in Next-Generation TRACER TM AAV Capsid and Vectorized Antibody Platform Technologies Proprietary AAV capsids to power second-generation efforts in Huntin
Voyager Therapeutics Transforms Pipeline and Increases Investment in Next-Generation TRACERTM AAV Capsid and Vectorized Antibody Platform Technologies Proprietary AAV capsids to power second-generation efforts in Huntington's disease and ALS, pre-clinical programs in spinal musc
Read more →VYGRVoyager Therapeutics Announces Strategic Shift and Leadership Transitions
Company focusing on rapidly moving VY-HTT01 into clinical development for Huntington’s disease and maximizing opportunities created by TRACERTM gene therapy technology platform and next-generation targeted AAV capsids Board members Michael Higgins and Glenn Pierce, M.D., Ph.D.,
Read more →VYGRVoyager Therapeutics Presents New Preclinical Data Showing Reduction of Pathological Tau with Vectorized Anti-Tau Antibody
Findings to be presented at the 24th Annual Meeting of the American Society of Gene and Cell Therapy Data demonstrate durable expression in CNS and may represent a new single-dose therapeutic strategy for treating various tauopathies CAMBRIDGE, Mass., May 12, 2021 (GLOBE NEWSWI
Read more →VYGRVoyager Therapeutics’ Novel Capsids Demonstrate Robust Delivery Across the Blood Brain Barrier, Widespread CNS Transduction in Non-Human Primates
Data to be presented at the 24th Annual Meeting of the American Society of Gene and Cell Therapy show up to 1000-fold higher transgene expression in the brain compared with conventional AAV gene therapy following IV administration CAMBRIDGE, Mass., May 11, 2021 (GLOBE NEWSWIRE)
Read more →VYGRVoyager Therapeutics Announces First Quarter 2021 Financial Results and Corporate Updates - On track to initiate Phase 1/2 trial of VY-HTT01 for Huntington's disease in the fourth quarter of 2021 - 8 presentations at Ame
Voyager Therapeutics Announces First Quarter 2021 Financial Results and Corporate Updates CAMBRIDGE, Mass., May 10, 2021 - Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for patients suffering from
Read more →VYGRVoyager Therapeutics Announces Upcoming Data Presentations at the American Society of Gene and Cell Therapy Virtual 2021 Annual Meeting
CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced multiple data presentations at the American Socie
Read more →VYGRVoyager Therapeutics Receives FDA Clearance of IND Application for Gene Therapy Candidate VY-HTT01 for Treatment of Huntington’s Disease
One-Time Gene Therapy to be Evaluated in Patients with Early Huntington’s Disease Initiation of VYTAL Phase 1/2 Clinical Trial at Multiple Sites Expected this Year CAMBRIDGE, Mass., April 26, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a clinical-stage g
Read more →VYGRVoyager Therapeutics, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm
Investors with losses are encouraged to contact the firm before March 24, 2021; click here to submit trade information LOS ANGELES, March 16, 2021 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Voyager Therapeut
Read more →VYGRVOYAGER THERAPEUTICS, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the Eastern District of New York against Voyager Therapeutics, Inc.
NEW YORK, March 03, 2021 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a announces that a federal securities class action lawsuit has been filed against Voyager Therapeutics, Inc. ("Voyager" or the "Company") (NASDAQ: VYGR) in the United States Dist
Read more →VYGRVoyager Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Corporate Updates Expects to Provide Complete Response to FDA Requests on IND Application for VY-HTT01 for Huntington's Disease in th
Voyager Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Corporate Updates CAMBRIDGE, Mass., February 25, 2021 - Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for pati
Read more →VYGRVOYAGER THERAPEUTICS, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Eastern District of New York against Voyager Therapeutics, Inc.
NEW YORK, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a announces that a federal securities class action lawsuit has been filed against Voyager Therapeutics, Inc. ("Voyager" or the "Company") (NASDAQ: VYGR) in the United States Distr
Read more →VYGRVoyager Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results and Participate in Upcoming Investor Conference
CAMBRIDGE, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, will report fourth quarter and full year 2020 financial results af
Read more →VYGRVoyager Therapeutics Provides Update on NBIb-1817 (VY-AADC) Gene Therapy Program
CAMBRIDGE, Mass., Feb. 02, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR) today announced that Neurocrine Biosciences, Inc. (Nasdaq: NBIX) provided notice of termination of the Parkinson’s disease portion of the collaboration agreement, effective August 2, 202
Read more →VYGRVoyager Therapeutics Announces Third Quarter 2020 Financial Results and Corporate Updates Plans to present three-year Phase 1b results of VY-AADC (NBIb-1817) in patients with Parkinson's disease at the Movement Disorder
Voyager Therapeutics Announces Third Quarter 2020 Financial Results and Corporate Updates Plans to present three-year Phase 1b results of VY-AADC (NBIb-1817) in patients with Parkinson's disease at the Movement Disorder Society (MDS) Virtual Congress 2020 Expects screening and
Read more →VYGRVoyager Therapeutics Provides Regulatory Update on VY-HTT01 Program
CAMBRIDGE, Mass., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced that it has received feedback from the U.S. Food a
Read more →VYGRVoyager Therapeutics Appoints Nancy Vitale to its Board of Directors
CAMBRIDGE, Mass., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced the addition of Nancy Vitale as an independent di
Read more →VYGRVoyager Therapeutics Appoints Michelle Quinn Smith as Chief Human Resources Officer
CAMBRIDGE, Mass., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced the appointment of Michelle Quinn Smith as Chief
Read more →VYGRVoyager Therapeutics Announces Upcoming Presentations at the International Parkinson and Movement Disorder Society Virtual Congress 2020
New Phase 1b Data of Investigational Gene Therapy Compound, VY-AADC (NBIb-1817), Evaluating Three-Year Safety and Clinical Outcomes in Patients with Advanced Parkinson’s Disease Voyager to Participate in Upcoming September Investor Conferences CAMBRIDGE, Mass., Sept. 03, 2020 (
Read more →VYGRVoyager Therapeutics Announces Second Quarter 2020 Financial Results and Corporate Updates Plans to present three-year Phase 1b results of VY-AADC (NBIb-1817) in patients with Parkinson's disease at the Movement Disorder
Voyager Therapeutics Announces Second Quarter 2020 Financial Results and Corporate Updates Plans to present three-year Phase 1b results of VY-AADC (NBIb-1817) in patients with Parkinson's disease at the Movement Disorder Society (MDS) Virtual Congress 2020 Expects screening and
Read more →VYGRVoyager Therapeutics Provides Update on AbbVie Vectorized Antibody Collaborations
CAMBRIDGE, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced the termination of its tau and alpha-synuclein vec
Read more →VYGRVoyager Therapeutics to Report Second Quarter 2020 Financial Results and Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, will report its second quarter 2020 financial results and corporat
Read more →VYGRVoyager Therapeutics Announces First Quarter 2020 Financial Results and Corporate Updates Announced 14 presentations at upcoming American Society of Gene and Cell Therapy (ASGCT) Virtual Annual Meeting highlighting Hunti
Voyager Therapeutics Announces First Quarter 2020 Financial Results and Corporate Updates Announced 14 presentations at upcoming American Society of Gene and Cell Therapy (ASGCT) Virtual Annual Meeting highlighting Huntington's disease, ALS SOD1, vectorized antibodies, novel cap
Read more →VYGRVoyager Therapeutics Announces Upcoming Data Presentations at the American Society of Gene and Cell Therapy Virtual 2020 Annual Meeting
CAMBRIDGE, Mass., April 29, 2020 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced multiple data presentations at the American Socie
Read more →VYGRVoyager Therapeutics Provides Update on the RESTORE-1 Parkinson’s Disease Trial
CAMBRIDGE, Mass., April 03, 2020 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today provided an update on the RESTORE-1 clinical trial of VY-AA
Read more →VYGRVoyager Therapeutics Announces Cancellation of Presentation and Webcast at the Barclays Global Healthcare Conference
CAMBRIDGE, Mass., March 09, 2020 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR) announced today the cancellation of the Company’s presentation and webcast at the Barclays Global Healthcare Conference, previously scheduled to take place on March 10, 2020 at 4:20 p.m
Read more →VYGRVoyager Therapeutics Announces Fourth Quarter and Full Year 2019 Financial Results and Corporate Updates Protocol amendment being implemented for ongoing RESTORE-1 trial of VY-AADC (NBIb-1817) for Parkinson's disease; pl
Voyager Therapeutics Announces Fourth Quarter and Full Year 2019 Financial Results and Corporate Updates Protocol amendment being implemented for ongoing RESTORE-1 trial of VY-AADC (NBIb-1817) for Parkinson's disease; plan to initiate RESTORE-2 trial in 2H 2020 Update on VY-HTT
Read more →VYGRVoyager Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results and Corporate Updates on March 3, 2020
CAMBRIDGE, Mass., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, will report fourth quarter and full year 2019 financial results af
Read more →VYGRVoyager Therapeutics Announces Third Quarter 2019 Financial Results and Corporate Highlights
Voyager Therapeutics Announces Third Quarter 2019 Financial Results and Corporate Highlights CAMBRIDGE, Mass., November 6, 2019 Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological
Read more →VYGRVoyager Therapeutics to Present at the Credit Suisse Healthcare Conference
CAMBRIDGE, Mass., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced a management presentation at the following upcomin
Read more →VYGRVoyager Therapeutics to Host Third Quarter 2019 Financial Results and Corporate Highlights Conference Call
CAMBRIDGE, Mass., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced that it will report its third quarter 2019 financi
Read more →VYGRVoyager Therapeutics to Present at Upcoming Investor Conferences in October 2019
CAMBRIDGE, Mass., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced management presentations at the following upcomin
Read more →VYGRVoyager Therapeutics to Present at Upcoming Investor Conferences in September 2019
CAMBRIDGE, Mass., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced management presentations at the following upcoming
Read more →VYGRVoyager Therapeutics Reports Second Quarter 2019 Financial Results and Corporate Highlights Gained worldwide rights to VY-HTT01 for Huntington's disease, expanding wholly-owned pipeline Presented additional Phase 1b resu
Voyager Therapeutics Reports Second Quarter 2019 Financial Results and Corporate Highlights Gained worldwide rights to VY-HTT01 for Huntington's disease, expanding wholly-owned pipeline Presented additional Phase 1b results for VY-AADC in patients with Parkinson's disease at th
Read more →VYGRVoyager Therapeutics to Host Second Quarter 2019 Financial Results and Corporate Highlights Conference Call
CAMBRIDGE, Mass., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced that it will report its second quarter 2019 financ
Read more →VYGRVoyager Therapeutics to Present at Upcoming Investor Conferences in August 2019
CAMBRIDGE, Mass., July 30, 2019 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced management presentations at the upcoming investor
Read more →VYGRVoyager Therapeutics Announces Restructured Gene Therapy Relationship with Sanofi Genzyme and Portfolio Update
Gains worldwide rights to VY-HTT01 for Huntington’s disease Resources to be reallocated to VY-HTT01 and other programs; intends to seek a partner for the SOD1 ALS program CAMBRIDGE, Mass., June 17, 2019 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-s
Read more →VYGRVoyager Therapeutics to Present at the Raymond James Life Sciences & MedTech Conference
CAMBRIDGE, Mass., June 11, 2019 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced management’s presentation at the upcoming investor
Read more →VYGRVoyager Therapeutics Announces Management Updates
CAMBRIDGE, Mass., May 20, 2019 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced the retirement of Dinah Sah, Ph.D. as Voyager’s chi
Read more →VYGRVoyager Therapeutics Reports First Quarter 2019 Financial Results and Corporate Highlights FDA grants orphan-drug designation for VY-HTT01 for Huntington's disease Begins strategic collaboration with Neurocrine Bioscienc
Voyager Therapeutics Reports First Quarter 2019 Financial Results and Corporate Highlights FDA grants orphan-drug designation for VY-HTT01 for Huntington's disease Begins strategic collaboration with Neurocrine Biosciences on gene therapy programs for Parkinson's disease and Fr
Read more →VYGRVoyager Therapeutics Announces New Data in Multiple Presentations at the American Society of Gene and Cell Therapy 2019 Annual Meeting
Voyager’s vectorized antibody program directed against tau demonstrates antibody distribution and expression levels in specific cell types that further facilitate studies with a vectorized antibody in animal models of disease New TRACER™ system enables the rapid discovery of nov
Read more →VYGRVoyager Therapeutics Announces Upcoming Data Presentations at the American Society of Gene and Cell Therapy 2019 Annual Meeting
CAMBRIDGE, Mass., April 15, 2019 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced multiple data presentations at the American Socie
Read more →VYGRVoyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 (c)(4)
CAMBRIDGE, Mass., April 03, 2019 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, granted restricted stock units and a non-qualified stock option t
Read more →VYGRVoyager Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference
CAMBRIDGE, Mass., April 02, 2019 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases today announced management’s presentation at the upcoming investor
Read more →VYGRVoyager Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Corporate Highlights Initiated RESTORE-1 Phase 2 trial for VY-AADC for Parkinson's disease Began IND-enabling preclinical studies for A
Voyager Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Corporate Highlights Initiated RESTORE-1 Phase 2 trial for VY-AADC for Parkinson's disease Began IND-enabling preclinical studies for ALS-SOD1 and Huntington's disease programs Recently announ
Read more →VYGRVoyager Therapeutics and AbbVie Announce Collaboration to Develop Vectorized Antibodies to Treat Parkinson’s Disease and Other Synucleinopathies
Deal expands collaborative efforts on vectorized antibodies to target pathological species of alpha-synuclein Voyager to receive $65 million upfront and up to $245 million in preclinical and Phase 1 option payments as well as potential development, regulatory, and commercial mil
Read more →VYGRVoyager Therapeutics to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced management’s presentation at the upcoming investor
Read more →VYGRVoyager Therapeutics to Host Fourth Quarter and Full Year 2018 Financial Results and Corporate Highlights Conference Call
CAMBRIDGE, Mass., Feb. 18, 2019 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced plans to host its fourth quarter and full year 201
Read more →VYGRVoyager Therapeutics Appoints Robert Hesslein as General Counsel
CAMBRIDGE, Mass., Jan. 22, 2019 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced the appointment of Robert Hesslein as general coun
Read more →VYGRVoyager Therapeutics to Appoint Omar Khwaja, M.D., Ph.D., as Chief Medical Officer
CAMBRIDGE, Mass., Jan. 15, 2019 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced the appointment of Omar Khwaja, M.D., Ph.D., as ch
Read more →VYGRVoyager Therapeutics Provides Updates for VY-AADC Clinical Program for Parkinson’s Disease
Voyager to increase the size of RESTORE-1 Phase 2 trial and to conduct a similarly-sized RESTORE-2 Phase 3 trial VY-AADC clinical program updates incorporate FDA feedback from Type B meeting CAMBRIDGE, Mass., Jan. 07, 2019 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:
Read more →VYGRVoyager Therapeutics Joins Michael J. Fox Foundation Initiatives and Education Campaigns to Accelerate the Development of New therapies and a Cure for Parkinson’s Disease
CAMBRIDGE, Mass., Dec. 17, 2018 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced joining multiple partnerships with The Michael J.
Read more →VYGRVoyager Therapeutics Announces First Patient Dosed in RESTORE-1, a Phase 2 Trial of VY-AADC Gene Therapy for the Treatment of Parkinson’s Disease
CAMBRIDGE, Mass., Dec. 10, 2018 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced dosing of the first patient in RESTORE-1, a Phase
Read more →VYGRVoyager Therapeutics Enters into Strategic Manufacturing Collaborations with Brammer Bio and Fujifilm Diosynth Biotechnologies
Collaborations to provide Voyager the ability and flexibility to transfer its manufacturing expertise across multiple high-quality vendors to support the development of its pipeline programs CAMBRIDGE, Mass., Nov. 29, 2018 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:
Read more →VYGRVoyager Therapeutics to Present at the Evercore ISI Healthcare Conference
CAMBRIDGE, Mass., Nov. 19, 2018 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases today announced management’s presentation at the upcoming investor
Read more →VYGRVoyager Therapeutics Announces Third Quarter 2018 Financial Results and Corporate Highlights One-time treatment with VY-AADC demonstrates durable improvements in motor function at 18 months and beyond from ongoing Phase
Voyager Therapeutics Announces Third Quarter 2018 Financial Results and Corporate Highlights One-time treatment with VY-AADC demonstrates durable improvements in motor function at 18 months and beyond from ongoing Phase 1b trial Recent preclinical results for Huntington's disea
Read more →VYGRVoyager Therapeutics Announces Positive Longer-Term Data for VY-AADC for Parkinson’s Disease
CAMBRIDGE, Mass., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced positive longer-term results from the open-label,
Read more →VYGRVoyager Therapeutics to Host Third Quarter 2018 Financial Results and Corporate Highlights Conference Call
CAMBRIDGE, Mass., Oct. 31, 2018 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced its third quarter 2018 financial results and corpor
Read more →VYGRVoyager Therapeutics Announces Preclinical Data for Huntington’s Disease and Amyotrophic Lateral Sclerosis Programs at the Congress of the European Society of Gene and Cell Therapy
One-time delivery of VY-HTT01 for Huntington’s disease achieves significant reduction of HTT gene expression in deeper tissues and outer layers of the brain of large animals One-time delivery of VY-SOD102 achieves significant reduction of SOD1 gene expression throughout a large
Read more →VYGRVoyager Therapeutics to Present at Investor Conferences in September
CAMBRIDGE, Mass., Aug. 28, 2018 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe neurological diseases, today announced management presentations at the upcoming investor conferences:
Read more →VYGRVoyager Therapeutics Announces Second Quarter 2018 Financial Results and Corporate Highlights Clinical data updates and regulatory feedback for VY-AADC during the quarter support planned pivotal program for Parkinson's d
Voyager Therapeutics Announces Second Quarter 2018 Financial Results and Corporate Highlights Clinical data updates and regulatory feedback for VY-AADC during the quarter support planned pivotal program for Parkinson's disease Pipeline programs progressing with updated preclini
Read more →VYGRVoyager Therapeutics to Present at Investor Conferences in August
CAMBRIDGE, Mass., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe neurological diseases, today announced management presentations at the upcoming investor conferences:
Read more →VYGRVoyager Therapeutics Announces Second Quarter 2018 Financial Results and Corporate Highlights Conference Call
CAMBRIDGE, Mass., July 31, 2018 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company focused on developing treatments for severe neurological diseases, today announced its second quarter 2018 financial results and corporate highlight
Read more →VYGRVoyager Therapeutics Receives FDA Guidance on Development Path for VY-AADC for Parkinson’s Disease and Provides Clinical Update
Voyager continues to plan to submit a BLA for VY-AADC based on its pivotal program and Type C meeting feedback Positive interim results with VY-AADC from the Phase 1 posterior trajectory trial supports the surgical approach and dose selection for the pivotal program CAMBRIDGE,
Read more →VYGRVoyager Therapeutics Appoints Andre Turenne as President and Chief Executive Officer
CAMBRIDGE, Mass., June 28, 2018 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases today announced the appointment of G. Andre Turenne as president and
Read more →VYGRVoyager Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted for VY-AADC for the Treatment of Parkinson’s Disease
CAMBRIDGE, Mass., June 21, 2018 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases today announced that the U.S. Food and Drug Administration (FDA) gra
Read more →VYGRVoyager Therapeutics Announces Management Change
CAMBRIDGE, Mass., May 29, 2018 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases today announced that Jane Henderson, Voyager’s chief financial office
Read more →VYGRVoyager Therapeutics Announces Additional Data at the American Society of Gene and Cell Therapy 2018 Annual Meeting
Voyager’s gene therapy vector for Friedreich’s ataxia prevents central and peripheral disease progression in preclinical model out to one year after a single administration Durable safety data generated with Voyager’s novel AAV gene therapy capsids along with widespread gene tra
Read more →VYGRVoyager Therapeutics Announces New Data at the American Society of Gene and Cell Therapy 2018 Annual Meeting
VY-SOD101 achieves meaningful suppression of disease-causing gene of ALS in large mammals after a one-time administration Results during the second half of 2018 from further delivery optimization efforts with VY-SOD101 and VY-HTT01 for Huntington’s disease expected to support IN
Read more →VYGRVoyager Therapeutics Announces First Quarter 2018 Financial Results and Corporate Highlights VY-AADC pivotal Phase 2-3 program for Parkinson's disease on track for first patient dosing during the middle of this year Camb
Voyager Therapeutics Announces First Quarter 2018 Financial Results and Corporate Highlights VY-AADC pivotal Phase 2-3 program for Parkinson's disease on track for first patient dosing during the middle of this year Cambridge, Mass., May 10, 2018 Voyager Therapeutics, Inc. (NAS
Read more →VYGRVoyager Therapeutics Announces Upcoming Data Presentations at the American Society of Gene and Cell Therapy 2018 Annual Meeting
Five oral presentations and 10 poster presentations focus on Voyager’s clinical and preclinical programs, novel capsid optimization efforts and manufacturing capabilities Investor and analyst breakfast event at ASGCT scheduled for Friday, May 18, 2018 CAMBRIDGE, Mass., April 30
Read more →VYGRVoyager Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results VY-AADC for advanced Parkinson's disease on track for start of planned global, pivotal Phase 2-3 program during the middle of this year Two
Voyager Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results VY-AADC for advanced Parkinson's disease on track for start of planned global, pivotal Phase 2-3 program during the middle of this year Two IND filings expected from the ALS, Huntington's disease a
Read more →VYGRVoyager Therapeutics Announces Longer-Term Data from Ongoing Phase 1b Trial of VY-AADC for Advanced Parkinson’s Disease
Robust and durable improvements in patients' motor function achieved with substantial reductions in use of daily oral levodopa and other Parkinson’s disease medications; one-time administrations of VY-AADC well-tolerated now out to three years in Cohort 1 In Cohort 2 at 18 month
Read more →VYGRVoyager Therapeutics to Host Fourth Quarter and Full Year 2017 Financial Results and Corporate Highlights Conference Call
CAMBRIDGE, Mass., Feb. 27, 2018 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company focused on developing treatments for severe neurological diseases, today announced its fourth quarter and full year 2017 financial results and corpo
Read more →VYGRVoyager Therapeutics to Present at Cowen Health Care Conference
CAMBRIDGE, Mass., Feb. 26, 2018 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe neurological diseases, today announced its presentation at the upcoming investor conference: Cowen 3
Read more →VYGRVoyager Therapeutics and AbbVie Announce Global Strategic Collaboration to Develop Potential New Treatments for Alzheimer’s Disease and Other Tau-Related Neurodegenerative Diseases
Collaboration to include development of gene therapies consisting of vectors to deliver monoclonal antibodies to the brain directed against tau Voyager to receive $69 million upfront payment and potentially up to $155 million in preclinical and Phase 1 option payments as well as
Read more →VYGRVoyager Therapeutics to Present at Leerink Partners Annual Global Healthcare Conference
CAMBRIDGE, Mass., Feb. 07, 2018 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe neurological diseases, today announced its presentation at the upcoming investor conference: LEERINK
Read more →VYGRVoyager Therapeutics Announces CEO Succession Plan for 2018 Cambridge, Mass.
Voyager Therapeutics Announces CEO Succession Plan for 2018 Cambridge, Mass., January 31, 2018 Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases today announced plans d
Read more →VYGRVoyager Therapeutics Announces FDA Clearance of Investigational New Drug Application for VY-AADC for Advanced Parkinson’s Disease
CAMBRIDGE, Mass., Jan. 23, 2018 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases today announced that the U.S. Food and Drug Administration (FDA) has
Read more →VYGRVoyager Therapeutics Highlights Lead Program VY-AADC for Advanced Parkinson’s Disease, AAV Novel Capsid and Delivery Optimization Efforts, and Pipeline Programs at its R&D Day
CAMBRIDGE, Mass., Nov. 16, 2017 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today at its R&D Day highlighted recent progress and plans for VY-A
Read more →VYGRVoyager Therapeutics to Present at Investor Conferences in November
CAMBRIDGE, Mass., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe neurological diseases, today announced management presentations at the upcoming investor conferences:
Read more →VYGRVoyager Therapeutics to Host R&D Day on November 16, 2017
CAMBRIDGE, Mass., Nov. 12, 2017 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, announced today it will host an R&D Day program and webcast for the
Read more →VYGRVoyager Therapeutics Announces Closing of Public Offering of Common Stock
CAMBRIDGE, Mass., Nov. 10, 2017 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced the closing of its underwritten public offering of
Read more →VYGRVoyager Therapeutics Announces Pricing of Public Offering of Common Stock Cambridge, Mass.
Voyager Therapeutics Announces Pricing of Public Offering of Common Stock Cambridge, Mass., November 7, 2017 Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today an
Read more →VYGRVoyager Therapeutics Announces Proposed Offering of Common Stock
CAMBRIDGE, Mass., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced that it is commencing an underwritten public offeri
Read more →VYGRVoyager Therapeutics Reports Third Quarter 2017 Financial Results and Corporate Highlights VY-AADC for advanced Parkinson's disease on track for start of global, pivotal phase 2-3 program Integration of novel capsid and
Voyager Therapeutics Reports Third Quarter 2017 Financial Results and Corporate Highlights VY-AADC for advanced Parkinson's disease on track for start of global, pivotal phase 2-3 program Integration of novel capsid and delivery optimization efforts expected to result in two IN
Read more →VYGRVoyager Therapeutics Announces Update to Parkinson’s Disease Program
Voyager to gain worldwide rights to VY-AADC program for advanced Parkinson’s disease Global, pivotal Phase 2-3 program for VY-AADC on track to dose the first patient during the second quarter of 2018 Voyager to host conference call today at 4:30 p.m. EDT CAMBRIDGE, Mass., Oct.
Read more →VYGRVoyager Therapeutics to Host Third Quarter 2017 Financial Results and Corporate Highlights Conference Call
CAMBRIDGE, Mass., Oct. 30, 2017 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company focused on developing treatments for severe neurological diseases, today announced its third quarter 2017 financial results and corporate highlights
Read more →VYGRVoyager Therapeutics Announces New Data Presentations at the Congress of the European Society of Gene and Cell Therapy
New data with novel AAV gene therapy capsids demonstrate widespread gene transfer to the brain and spinal cord of non-human primates after a single intravenous administration Additional studies at Voyager are underway in non-human primates with these novel capsids and other nove
Read more →VYGRVoyager Therapeutics Announces Multiple Data Presentations at the Congress of the European Society of Gene and Cell Therapy
CAMBRIDGE, Mass., Oct. 06, 2017 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases announced today multiple data presentations at the Congress of the E
Read more →VYGRVoyager Therapeutics to Present at Investor Conferences in October
CAMBRIDGE, Mass., Oct. 03, 2017 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe neurological diseases, today announced management presentations at the upcoming investor conferences:
Read more →VYGRVoyager Therapeutics Appoints Matthew P. Ottmer as Chief Operating Officer
CAMBRIDGE, Mass., Sept. 18, 2017 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases announced today the appointment of Matthew P. Ottmer as chief opera
Read more →VYGRVoyager Therapeutics Announces Positive Results from Ongoing Phase 1b Trial of VY-AADC01 for Advanced Parkinson’s Disease
VY-AADC01 improved multiple measures of patients’ motor function and activities of daily living in Cohorts 2 and 3 Robust and durable clinical effects achieved with substantial reductions in daily oral levodopa use and other Parkinson’s medications; one-time administrations of V
Read more →VYGRVoyager Therapeutics to Participate in September Investor Conferences
CAMBRIDGE, Mass., Aug. 30, 2017 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe neurological diseases today announced its participation at the upcoming investor conferences: 2017 W
Read more →VYGRVoyager Therapeutics Reports Second Quarter 2017 Financial Results and Corporate Highlights Lead program VY-AADC for advanced Parkinson's disease progressing towards pivotal trials Cambridge, Mass.
Voyager Therapeutics Reports Second Quarter 2017 Financial Results and Corporate Highlights Lead program VY-AADC for advanced Parkinson's disease progressing towards pivotal trials Cambridge, Mass., August 8, 2017 Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene
Read more →VYGRVoyager Therapeutics to Host Second Quarter 2017 Financial Results and Corporate Highlights Conference Call
CAMBRIDGE, Mass., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe neurological diseases, today announced its second quarter 2017 financial results and corporate highli
Read more →VYGRVoyager Therapeutics Announces Publication from the California Institute of Technology of a Second-Generation Gene Therapy Capsid Demonstrating Further Enhanced Gene Transfer to the Brain
A single, intravenous administration of a novel AAV capsid provided up to 100-fold increase in gene transfer to the central nervous system in a preclinical model compared to the historical standard AAV9 Key translational studies are underway by Voyager to evaluate this and other
Read more →VYGRVoyager Therapeutics Announces Clinical Trial Update with VY-AADC01 for Advanced Parkinson’s Disease
CAMBRIDGE, Mass., June 26, 2017 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe neurological diseases, today announced dosing of the first patient in a Phase 1 trial aimed at furthe
Read more →VYGRVoyager Therapeutics to Attend Upcoming Investor Conferences
CAMBRIDGE, Mass., June 02, 2017 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe neurological diseases, today announced that Steven Paul, M.D., president and chief executive officer,
Read more →VYGRVoyager Therapeutics Selects Lead Clinical Candidate for Huntington’s Disease
CAMBRIDGE, Mass., June 01, 2017 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe neurological diseases, today announced the selection of VY-HTT01, a clinical candidate for the treatm
Read more →VYGRVoyager Therapeutics Reports First Quarter 2017 Financial Results and Corporate Highlights VY-AADC01 interim Phase 1b data recently presented at American Academy of Neurology and American Association of Neurological Surg
Voyager Therapeutics Reports First Quarter 2017 Financial Results and Corporate Highlights VY-AADC01 interim Phase 1b data recently presented at American Academy of Neurology and American Association of Neurological Surgeons meetings; program on track to report 6-month data from
Read more →VYGRVoyager Therapeutics to Host First Quarter 2017 Financial Results and Corporate Highlights Conference Call
CAMBRIDGE, Mass., May 04, 2017 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), today announced its first quarter 2017 financial results
Read more →VYGRVoyager Therapeutics Announces Additional Results from Phase 1b Trial of VY-AADC01 for Advanced Parkinson’s Disease
Improved Functional and Quality of Life Data Presented at the American Academy of Neurology (AAN) Meeting in Boston, MA Surgical Delivery Data Presented at the American Association of Neurological Surgeons (AANS) Meeting in Los Angeles, CA CAMBRIDGE, Mass., April 25, 2017 (GLOB
Read more →VYGRVoyager Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Corporate Highlights
Lead program VY-AADC01 for advanced Parkinson’s disease on track to report 6-month data from Cohort 3 and longer-term data from Cohorts 1 and 2 in mid-year 2017 VY-AADC01 Phase 1b data accepted as emerging (late-breaking) oral presentation at the upcoming American Academy of Neu
Read more →VYGRVoyager Therapeutics to Host Fourth Quarter and Full Year 2016 Financial Results Conference call
CAMBRIDGE, Mass., March 08, 2017 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), today announced its fourth quarter and full year 2016
Read more →VYGRVoyager Therapeutics Supports Rare Disease Day and Global Movement to Raise Awareness for Rare Diseases
CAMBRIDGE, Mass., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), today recognizes the 10th Annual Rare Disease Day dedic
Read more →VYGRVoyager Therapeutics Announces Lead Clinical Candidate Selection for Monogenic Form of Amyotrophic Lateral Sclerosis (ALS)
VY-SOD101 Selected Based on Robust Delivery and Knock-Down of Toxic SOD1 in Preclinical Models Program On Track for IND filing during 4Q:17 CAMBRIDGE, Mass., Feb. 13, 2017 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company develo
Read more →VYGRVoyager Therapeutics Announces Publication of Vectored Anti-Tau Monoclonal Antibody Study in The Journal of Neuroscience
Single Administration of AAV-Vectored Anti-Tau Monoclonal Antibody Markedly Reduced Tau Pathology in Preclinical Model Voyager Optimizing the Delivery of Anti-Tau Monoclonal Antibodies with its Proprietary VY-TAU01 Preclinical Program CAMBRIDGE, Mass., Jan. 25, 2017 (GLOBE NEWS
Read more →VYGRVoyager Therapeutics Announces Updates from Phase 1b Trial of VY-AADC01 for Advanced Parkinson’s Disease
Cohort 3 Enrollment Complete with Increased Coverage of the Putamen Observed Cohort 3 On Track for Six-Month Data Update Mid-2017 CAMBRIDGE, Mass., Jan. 20, 2017 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-
Read more →VYGRVoyager Therapeutics Elects Wendy Dixon, Ph.D. and Glenn Pierce, M.D., Ph.D. to Board of Directors
CAMBRIDGE, Mass., Jan. 05, 2017 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), today announced the appointments of Wendy L. Dixon, Ph.
Read more →VYGRVoyager Therapeutics Appoints Jane Pritchett Henderson as Chief Financial Officer
CAMBRIDGE, Mass., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), today announced the appointment of Jane Pritchett Hende
Read more →VYGRVoyager Therapeutics to Attend Upcoming Investor Conference
CAMBRIDGE, Mass., Dec. 09, 2016 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), today announced that Bernard Ravina, M.D, M.S., vice pr
Read more →VYGRVoyager Therapeutics Announces Positive Interim Results from Phase 1b Trial of VY-AADC01 for Advanced Parkinson s Disease VY-AADC01 dose-dependently improved measures of motor function and enhanced response to levodopa a
Voyager Therapeutics Announces Positive Interim Results from Phase 1b Trial of VY-AADC01 for Advanced Parkinson s Disease VY-AADC01 dose-dependently improved measures of motor function and enhanced response to levodopa at six and twelve months; administration of VY-AADC01 was we
Read more →VYGRVoyager Therapeutics and REGENXBIO Announce Exercise of Options for Rights to NAV Vectors
CAMBRIDGE, Mass., and ROCKVILLE, Md., Nov. 29, 2016 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), and REGENXBIO Inc. (Nasdaq:RGNX), a
Read more →VYGRVoyager Therapeutics Provides Third Quarter 2016 Investor Update
VY-AADC01 program for advanced Parkinson’s disease on track for interim Phase 1b results in early December Preclinical pipeline advances along with prioritization Recent licensing deal increases access to more novel AAV capsids CAMBRIDGE, Mass., Nov. 10, 2016 (GLOBE NEWSWIRE)
Read more →VYGRVoyager Therapeutics to Host Third Quarter 2016 Investor Update Call
CAMBRIDGE, Mass., Nov. 01, 2016 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), today announced its third quarter 2016 investor update
Read more →VYGRVoyager Therapeutics Announces Planned Transition Process for Chief Financial Officer
CAMBRIDGE, Mass., Oct. 18, 2016 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), today announced a transition process for Jeff Goater, V
Read more →VYGRVoyager Therapeutics Licenses Novel Gene Therapy Capsids from the California Institute of Technology
CAMBRIDGE, Mass., Sept. 15, 2016 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), today announced a co-exclusive worldwide license agree
Read more →VYGRVoyager Therapeutics and CHDI Foundation Collaborate to Develop Novel Gene Therapy for Huntington’s Disease
CAMBRIDGE, Mass., Sept. 12, 2016 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS) today announced a research collaboration with CHDI Foun
Read more →VYGRVoyager Therapeutics Provides Second Quarter 2016 Investor Update VY-AADC01 Phase 1b Study for Advanced Parkinson's Disease On Track to Report Six-Month Safety, Motor Function, and Biomarker Data from Cohorts 1 and 2 by
Voyager Therapeutics Provides Second Quarter 2016 Investor Update VY-AADC01 Phase 1b Study for Advanced Parkinson's Disease On Track to Report Six-Month Safety, Motor Function, and Biomarker Data from Cohorts 1 and 2 by Year-End 2016 Pipeline Advances with Selection of Lead Cli
Read more →VYGRVoyager Therapeutics Initiates Third Cohort in Ongoing Phase 1b Clinical Trial of VY-AADC01 in Advanced Parkinson’s Disease
CAMBRIDGE, Mass., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), today announced dosing of the first patient in the thir
Read more →VYGRVoyager Therapeutics to Host Second Quarter 2016 Investor Update Call
CAMBRIDGE, Mass., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), today announced its second quarter 2016 investor update
Read more →VYGRVoyager Therapeutics Announces Interim Phase 1b Surgical Results for VY-AADC01 in Advanced Parkinson’s Disease
Data Presented at the 20th International Congress of Parkinson’s Disease & Movement Disorders in Berlin, Germany VY-AADC01 Continues to Demonstrate Safety with Increasing Coverage of Targeted Regions of the Brain Phase 1b Study On Track to Report Interim Motor Symptom and Bioma
Read more →VYGRVoyager Therapeutics Provides First Quarter 2016 Investor Update Enrollment Completed in 2 nd Cohort of Ongoing Phase 1b Clinical Trial of VY-AADC01 in Advanced Parkinson's Disease VY-AADC01 Interim Phase 1b Results to b
Voyager Therapeutics Provides First Quarter 2016 Investor Update Enrollment Completed in 2nd Cohort of Ongoing Phase 1b Clinical Trial of VY-AADC01 in Advanced Parkinson's Disease VY-AADC01 Interim Phase 1b Results to be Presented at 20th International Congress of Parkinson's D
Read more →VYGRVoyager Therapeutics to Host First Quarter 2016 Investor Update Call
CAMBRIDGE, Mass., May 05, 2016 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), today announced that it will host its first quarter 2016
Read more →VYGRVoyager Therapeutics Highlights Programs in Parkinson’s Disease and ALS; Announces Expansion of CNS Pipeline at R&D Day
Top-Line Proof-of-Concept Clinical Data for Parkinson’s Disease Program (VY-AADC01) Remains on Track for the Fourth Quarter of 2016 IND Filing for ALS Program (VY-SOD101) Targeted for Late 2017 Two New Gene Therapy Programs Targeting Tau and Nav1.7 Announced CAMBRIDGE, Mass.,
Read more →VYGRVoyager Therapeutics (Nasdaq: VYGR) to Ring The Nasdaq Stock Market Opening Bell
ADVISORY, April 25, 2016 (GLOBE NEWSWIRE) -- Voyager Therapeutics (Nasdaq:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), will visit the Nasdaq MarketSite in Times Square ahead of the compa
Read more →VYGRVoyager Therapeutics to Host R&D Day and Webcast on April 29, 2016
CAMBRIDGE, Mass., April 14, 2016 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), today announced that the Company will host an R&D Day
Read more →VYGRVoyager Therapeutics Provides Fourth Quarter and Full Year 2015 Investor Update Top-line Clinical Proof-of-Concept Data for VY-AADC01 for Advanced Parkinson's Disease On Track for Release in the Fourth Quarter of 2016 St
Voyager Therapeutics Provides Fourth Quarter and Full Year 2015 Investor Update Top-line Clinical Proof-of-Concept Data for VY-AADC01 for Advanced Parkinson's Disease On Track for Release in the Fourth Quarter of 2016 Strong Cash Position Projected to Support Operations into 20
Read more →VYGRVoyager Therapeutics to Present at Alliance for Regenerative Medicine’s 4th Annual Cell & Gene Therapy Investor Day
CAMBRIDGE, Mass., March 14, 2016 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), today announced that Steven Paul, M.D., president and
Read more →VYGRVoyager Therapeutics to Host Fourth Quarter and Full Year 2015 Investor Update Call
CAMBRIDGE, Mass., March 10, 2016 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), today announced that it will host its fourth quarter a
Read more →VYGRVoyager Therapeutics to Present at Cowen and Company 36th Annual Health Care Conference
CAMBRIDGE, Mass., Feb. 29, 2016 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), today announced that Steven Paul, M.D., president and c
Read more →VYGRVoyager Therapeutics Promotes Jeff Goater to Chief Financial Officer
CAMBRIDGE, Mass., Feb. 02, 2016 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), today announced it has promoted Jeff Goater, former sen
Read more →VYGRVoyager Therapeutics Added to Russell 2000 , 3000 and Global Indexes
CAMBRIDGE, Mass., Dec. 18, 2015 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), today announced that it has been added to the Russell 2
Read more →VYGRVoyager Therapeutics Reports Third Quarter 2015 Financial Results I nitia l public offering raised $72.7 million in net proceeds Proof-of-concept data for lead clinical program , VY-AADC01, for Parkinson's disease expect
Voyager Therapeutics Reports Third Quarter 2015 Financial Results Initial public offering raised $72.7 million in net proceeds Proof-of-concept data for lead clinical program, VY-AADC01, for Parkinson's disease expected in second half of 2016 Cambridge, Mass., December 17, 201
Read more →VYGRVoyager Therapeutics Announces Closing of Initial Public Offering, Including Full Exercise of Option to Purchase Additional Shares
CAMBRIDGE, Mass., Nov. 16, 2015 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), today announced the closing of its initial public offer
Read more →VYGRVoyager Therapeutics Announces Pricing of Initial Public Offering
CAMBRIDGE, Mass., Nov. 10, 2015 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc., a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), today announced the pricing of its initial public offering of 5,000,0
Read more →Competitive Position
How VYGR ranks across every disease it competes inCompetitive Position is a premium feature
See how VYGR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial